DNA damage emergency: Cellular garbage disposal to the rescue

Oncogene

Volumn 33, Issue 7, 2014, Pages 805-813

  Stone, H R ^a   Morris, J R ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

53BP1; DNA repair; POH1; proteasome; ubiquitin

Indexed keywords

ANIMALS; ANTINEOPLASTIC AGENTS; CHROMATIN; DNA DAMAGE; DNA REPAIR; DNA-BINDING PROTEINS; HUMANS; NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; UBIQUITINATION;

EID: 84894071974     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2013.60     Document Type: Review

References (145)

1. Hochstrasser M. Evolution and function of ubiquitin-like protein-conjugation systems. Nat Cell Biol 2000; 2: E153-E157.
2. Wang C, Xi J, Begley TP, Nicholson LK. Solution structure of ThiS and implications for the evolutionary roots of ubiquitin. Nat Struct Mol Biol 2001; 8: 47-51.
3. Goldstein G, Scheid M, Hammerling U, Boyse EA, Schlesinger DH, Niall HD. Isolation of a polypeptide that has lymphocyte-differentiating properties and is probably represented universally in living cells. Proc Natl Acad Sci USA 1975; 72: 11-15.
4. Hicke L. Protein regulation by monoubiquitin. Nat Rev Mol Cell Biol 2001; 2: 195-201.
5. Ciechanover A, Heller H, Katzetzion R, Hershko A. Activation of the heat-stable polypeptide of the ATP-dependent proteolytic system. Proc Natl Acad Sci USA Biol Sci 1981; 78: 761-765.
6. Hershko A, Heller H, Elias S, Ciechanover A. Components of ubiquitin-protein ligase system. Resolution, affinity purification, and role in protein breakdown. J Biol Chem 1983; 258: 8206-8214.
7. Amerik AY, Hochstrasser M. Mechanism and function of deubiquitinating enzymes. Biochim Biophys Acta 2004; 1695: 189-207.
8. Kirisako T, Kamei K, Murata S, Kato M, Fukumoto H, Kanie M et al. A ubiquitin ligase complex assembles linear polyubiquitin chains. EMBO J 2006; 25: 4877-4887.
9. Goldknopf IL, Busch H. Isopeptide linkage between nonhistone and histone-2A polypeptides of chromosomal conjugate-proteins-A24. Proc Natl Acad Sci USA 1977; 74: 864-868.
10. Peng JM, Schwartz D, Elias JE, Thoreen CC, Cheng DM, Marsischky G et al. A proteomics approach to understanding protein ubiquitination. Nat Biotechnol 2003; 21: 921-926.
11. Varadan R, Walker O, Pickart C, Fushman D. Structural properties of polyubiquitin chains in solution. J Mol Biol 2002; 324: 637-647.
12. Fushman D, Walker O. Exploring the linkage dependence of polyubiquitin conformations using molecular modeling. J Mol Biol 2010; 395: 803-814.
13. Kim HT, Kim KP, Lledias F, Kisselev AF, Scaglione KM, Skowyra D et al. Certain pairs of ubiquitin-conjugating enzymes (E2s) and ubiquitin-protein ligases (E3s) synthesize nondegradable forked ubiquitin chains containing all possible isopeptide linkages. J Biol Chem 2007; 282: 17375-17386.
14. Sowa ME, Bennett EJ, Gygi SP, Harper JW. Defining the human deubiquitinating enzyme interaction landscape. Cell 2009; 138: 389-403.
15. Komander D, Clague MJ, Urbe S. Breaking the chains: structure and function of the deubiquitinases. Nat Rev Mol Cell Biol 2009; 10: 550-563.
16. Jacobson AD, Zhang NY, Xu P, Han KJ, Noone S, Peng J et al. The lysine 48 and lysine 63 ubiquitin conjugates are processed differently by the 26 s proteasome. J Biol Chem 2009; 284: 35485-35494.
17. Peth A, Besche HC, Goldberg AL. Ubiquitinated proteins activate the proteasome by binding to Usp14/Ubp6, which causes 20S gate opening. Mol Cell 2009; 36: 794-804.
18. Peth A, Uchiki T, Goldberg AL. ATP-dependent steps in the binding of ubiquitin conjugates to the 26S proteasome that commit to degradation. Mol Cell 2010; 40: 671-681.
19. Johnson ES, Ma PCM, Ota IM, Varshavsky A. A proteolytic pathway that recognizes ubiquitin as a degradation signal. J Biol Chem 1995; 270: 17442-17456.
20. Matilla A, Gorbea C, Einum DD, Townsend J, Michalik A, van Broeckhoven C et al. Association of ataxin-7 with the proteasome subunit S4 of the 19S regulatory complex. Hum Mol Genet 2001; 10: 2821-2831.
21. Cooper EM, Cutcliffe C, Kristiansen TZ, Pandey A, Pickart CM, Cohen RE. K63-specific deubiquitination by two JAMM/MPN\+ complexes: BRISC-associated Brcc36 and proteasomal Poh1. EMBO J 2009; 28: 621-631.
22. Xu P, Duong DM, Seyfried NT, Cheng DM, Xie Y, Robert J et al. Quantitative proteomics reveals the function of unconventional ubiquitin chains in proteasomal degradation. Cell 2009; 137: 133-145.
23. Virdee S, Ye Y, Nguyen DP, Komander D, Chin JW. Engineered diubiquitin synthesis reveals Lys29-isopeptide specificity of an OTU deubiquitinase. Nat Chem Biol 2010; 6: 750-757.
24. Nishikawa H, Ooka S, Sato K, Arima K, Okamoto J, Klevit RE et al. Mass spectrometric and mutational analyses reveal Lys-6-linked polyubiquitin chains catalyzed by BRCA1-BARD1 ubiquitin ligase. J Biol Chem 2003; 279: 3916-3924.
25. Ben-Saadon R, Zaaroor D, Ziv T, Ciechanover A. The polycomb protein Ring1B generates self atypical mixed ubiquitin chains required for its in vitro histone H2A ligase activity. Mol Cell 2006; 24: 701-711.
26. Patterson-Fortin J, Shao G, Bretscher H, Messick TE, Greenberg RA. Differential regulation of JAMM domain deubiquitinating enzyme activity within the RAP80 complex. J Biol Chem 2010; 285: 30971-30981.
27. Stewart GS, Wang B, Bignell CR, Taylor AM, Elledge SJ. MDC1 is a mediator of the mammalian DNA damage checkpoint. Nature 2003; 421: 961-966.
28. Mochan TA, Venere M, DiTullio Jr. RA, Halazonetis TD. 53BP1 and NFBD1/MDC1-Nbs1 function in parallel interacting pathways activating ataxia-telangiectasia mutated (ATM) in response to DNA damage. Cancer Res 2003; 63: 8586-8591.
29. Lou Z, Chini CC, Minter-Dykhouse K, Chen J. Mediator of DNA damage checkpoint protein 1 regulates BRCA1 localization and phosphorylation in DNA damage checkpoint control. J Biol Chem 2003; 278: 13599-13602.
30. Huen MS, Grant R, Manke I, Minn K, Yu X, Yaffe MB et al. RNF8 transduces the DNA-damage signal via histone ubiquitylation and checkpoint protein assembly. Cell 2007; 131: 901-914.
31. Kolas NK, Chapman JR, Nakada S, Ylanko J, Chahwan R, Sweeney FD et al. Orchestration of the DNA-damage response by the RNF8 ubiquitin ligase. Science 2007; 318: 1637-1640.
32. Mailand N, Bekker-Jensen S, Faustrup H, Melander F, Bartek J, Lukas C et al. RNF8 ubiquitylates histones at DNA double-strand breaks and promotes assembly of repair proteins. Cell 2007; 131: 887-900.
33. Wang B, Elledge SJ. Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci USA 2007; 104: 20759-20763.
34. Doil C, Mailand N, Bekker-Jensen S, Menard P, Larsen DH, Pepperkok R et al. RNF168 binds and amplifies ubiquitin conjugates on damaged chromosomes to allow accumulation of repair proteins. Cell 2009; 136: 435-446.
35. Stewart GS, Panier S, Townsend K, Al-Hakim AK, Kolas NK, Miller ES et al. The RIDDLE syndrome protein mediates a ubiquitin-dependent signaling cascade at sites of DNA damage. Cell 2009; 136: 420-434.
36. Wang B, Matsuoka S, Ballif BA, Zhang D, Smogorzewska A, Gygi SP et al. Abraxas and RAP80 form a BRCA1 protein complex required for the DNA damage response. Science 2007; 316: 1194-1198.
37. Huang J, Huen MS, Kim H, Leung CC, Glover JN, Yu X et al. RAD18 transmits DNA damage signalling to elicit homologous recombination repair. Nat Cell Biol 2009; 11: 592-603.
38. Marteijn JA, Bekker-Jensen S, Mailand N, Lans H, Schwertman P, Gourdin AM et al. Nucleotide excision repair-induced H2A ubiquitination is dependent on MDC1 and RNF8 and reveals a universal DNA damage response. J Cell Biol 2009; 186: 835-847.
39. Mallette FA, Mattiroli F, Cui G, Young LC, Hendzel MJ, Mer G et al. RNF8-and RNF168-dependent degradation of KDM4A/JMJD2A triggers 53BP1 recruitment to DNA damage sites. EMBO J 2012; 31: 1865-1878.
40. Butler LR, Densham RM, Jia J, Garvin AJ, Stone HR, Shah V et al. The proteasomal de-ubiquitinating enzyme POH1 promotes the double-strand DNA break response. EMBO J 2012; 31: 3918-3934.
41. Mattiroli F, Vissers JH, van Dijk WJ, Ikpa P, Citterio E, Vermeulen W et al. RNF168 ubiquitinates K13-15 on H2A/H2AX to drive DNA damage signaling. Cell 2012; 150: 1182-1195.
42. Yan J, Jetten AM. RAP80 and RNF8, key players in the recruitment of repair proteins to DNA damage sites. Cancer Lett 2008; 271: 179-190.
43. Wu J, Liu C, Chen J, Yu X. Rap80 is important for genomic stability and is required for stabilizing the BRCA1-A complex at DNA damage sites in vivo. J Biol Chem 2012; 287: 22919-22926.
44. Sobhian B, Shao G, Lilli DR, Culhane AC, Moreau LA, Xia B et al. RAP80 targets BRCA1 to specific ubiquitin structures at DNA damage sites. Science 2007; 316: 1198-1202.
45. Nakada S, Yonamine RM, Matsuo K. RNF8 regulates assembly of RAD51 at DNA double-strand breaks in the absence of BRCA1 and 53BP1. Cancer Res 2012; 72: 4974-4983.
46. Mott C, Symington LS. RAD51-independent inverted-repeat recombination by a strand-annealing mechanism. DNA Repair 2011; 10: 408-415.
47. Sigurdsson S, Van Komen S, Bussen W, Schild D, Albala JS, Sung P. Mediator function of the human Rad51B-Rad51C complex in Rad51/RPA-catalyzed DNA strand exchange. Genes Develop 2001; 15: 3308-3318.
48. Dou H, Huang C, Singh M, Carpenter PB, Yeh ET. Regulation of DNA repair through deSUMOylation and SUMOylation of replication protein A complex. Mol Cell 2010; 39: 333-345.
49. Galanty Y, Belotserkovskaya R, Coates J, Jackson SP. RNF4, a SUMO-targeted ubiquitin E3 ligase, promotes DNA double-strand break repair. Genes Develop 2012; 26: 1179-1195.
50. Luo K, Zhang H, Wang L, Yuan J, Lou Z. Sumoylation of MDC1 is important for proper DNA damage response. EMBO J 2012; 31: 3008-3019.
51. Yin Y, Seifert A, Chua JS, Maure JF, Golebiowski F, Hay RT. SUMO-targeted ubiquitin E3 ligase RNF4 is required for the response of human cells to DNA damage. Genes Develop 2012; 26: 1196-1208.
52. Vyas R, Kumar R, Clermont F, Helfricht A, Kalev P, Sotiropoulou P et al. RNF4 is required for DNA double-strand break repair in vivo. Cell Death Differ 2012; 20: 490-502.
53. Zhang D, Zaugg K, Mak TW, Elledge SJ. A role for the deubiquitinating enzyme USP28 in control of the DNA-damage response. Cell 2006; 126: 529-542.
54. Popov N, Herold S, Llamazares M, Schulein C, Eilers M. Fbw7 and Usp28 regulate Myc protein stability in response to DNA damage. Cell Cycle 2007; 6: 2327-2331.
55. Nicassio F, Corrado N, Vissers JH, Areces LB, Bergink S, Marteijn JA et al. Human USP3 is a chromatin modifier required for S phase progression and genome stability. Curr Biol 2007; 17: 1972-1977.
56. Joo HY, Zhai L, Yang C, Nie S, Erdjument-Bromage H, Tempst P et al. Regulation of cell cycle progression and gene expression by H2A deubiquitination. Nature 2007; 449: 1068-1072.
57. Nakada S, Tai I, Panier S, Al-Hakim A, Iemura S, Juang YC et al. Non-canonical inhibition of DNA damage-dependent ubiquitination by OTUB1. Nature 2010; 466: 941-946.
58. Wiener R, Zhang X, Wang T, Wolberger C. The mechanism of OTUB1-mediated inhibition of ubiquitination. Nature 2012; 483: 618-622.
59. Juang YC, Landry MC, Sanches M, Vittal V, Leung CC, Ceccarelli DF et al. OTUB1 co-opts Lys48-linked ubiquitin recognition to suppress E2 enzyme function. Mol Cell 2012; 45: 384-397.
60. Sato Y, Yamagata A, Goto-Ito S, Kubota K, Miyamoto R, Nakada S et al. Molecular basis of Lys-63-linked polyubiquitination inhibition by the interaction between human deubiquitinating enzyme OTUB1 and ubiquitin- conjugating enzyme UBC13. J Biol Chem 2012; 287: 25860-25868.
61. Feng L, Wang J, Chen J. The Lys63-specific deubiquitinating enzyme BRCC36 is regulated by two scaffold proteins localizing in different subcellular compartments. J Biol Chem 2010; 285: 30982-30988.
62. Shao G, Lilli DR, Patterson-Fortin J, Coleman KA, Morrissey DE, Greenberg RA. The Rap80-BRCC36 de-ubiquitinating enzyme complex antagonizes RNF8-Ubc13-dependent ubiquitination events at DNA double strand breaks. Proc Natl Acad Sci USA 2009; 106: 3166-3171.
63. Acs K, Luijsterburg MS, Ackermann L, Salomons FA, Hoppe T, Dantuma NP. The AAA-ATPase VCP/p97 promotes 53BP1 recruitment by removing L3MBTL1 from DNA double-strand breaks. Nat Struct Mol Biol 2011; 18: 1345-1350.
64. Meerang M, Ritz D, Paliwal S, Garajova Z, Bosshard M, Mailand N et al. The ubiquitin-selective segregase VCP/p97 orchestrates the response to DNA double-strand breaks. Nat Cell Biol 2011; 13: 1376-1382.
65. Dantuma NP, Groothuis TA, Salomons FA, Neefjes J. A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling. J Cell Biol 2006; 173: 19-26.
66. Shi W, Ma Z, Willers H, Akhtar K, Scott SP, Zhang J et al. Disassembly of MDC1 foci is controlled by ubiquitin-proteasome-dependent degradation. J Biol Chem 2008; 283: 31608-31616.
67. Murakawa Y, Sonoda E, Barber LJ, Zeng W, Yokomori K, Kimura H et al. Inhibitors of the proteasome suppress homologous DNA recombination in mammalian cells. Cancer Res 2007; 67: 8536-8543.
68. Jacquemont C, Taniguchi T. Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Res 2007; 67: 7395-7405.
69. Gudmundsdottir K, Lord CJ, Ashworth A. The proteasome is involved in determining differential utilization of double-strand break repair pathways. Oncogene 2007; 26: 7601-7606.
70. Ben-Aroya S, Agmon N, Yuen K, Kwok T, McManus K, Kupiec M et al. Proteasome nuclear activity affects chromosome stability by controlling the turnover of Mms22, a protein important for DNA repair. PLoS Genet 2010; 6: e1000852.
71. Liu H, Buus R, Clague MJ, Urbe S. Regulation of ErbB2 receptor status by the proteasomal DUB POH1. PLoS ONE 2009; 4: e5544.
72. Hanna J, Leggett DS, Finley D. Ubiquitin depletion as a key mediator of toxicity by translational inhibitors. Mol Cell Biol 2003; 23: 9251-9261.
73. Postow L, Ghenoiu C, Woo EM, Krutchinsky AN, Chait BT, Funabiki H. Ku80 removal from DNA through double strand break-induced ubiquitylation. J Cell Biol 2008; 182: 467-479.
74. Krogan NJ, Lam MH, Fillingham J, Keogh MC, Gebbia M, Li J et al. Proteasome involvement in the repair of DNA double-strand breaks. Mol Cell 2004; 16: 1027-1034.
75. Kuehn L, Dahlmann B. Structural and functional properties of proteasome activator PA28. Mol Biol Rep 1997; 24: 89-93.
76. Ustrell V, Hoffman L, Pratt G, Rechsteiner M. PA200, a nuclear proteasome activator involved in DNA repair. EMBO J 2002; 21: 3516-3525.
77. Blickwedehl J, Agarwal M, Seong C, Pandita RK, Melendy T, Sung P et al. Role for proteasome activator PA200 and postglutamyl proteasome activity in genomic stability. Proc Natl Acad Sci USA 2008; 105: 16165-16170.
78. Blickwedehl J, McEvoy S, Wong I, Kousis P, Clements J, Elliott R et al. Proteasomes and proteasome activator 200 kDa (PA200) accumulate on chromatin in response to ionizing radiation. Radiat Res 2007; 167: 663-674.
79. Levy-Barda A, Lerenthal Y, Davis AJ, Chung YM, Essers J, Shao Z et al. Involvement of the nuclear proteasome activator PA28gamma in the cellular response to DNA double-strand breaks. Cell Cycle 2011; 10: 24.
80. Kim HT, Goldberg AL. S5a/Rpn10, a UIM-protein, as a universal substrate for ubiquitination. Methods Mol Biol 2012; 832: 653-660.
81. Kim HT, Kim KP, Uchiki T, Gygi SP, Goldberg AL. S5a promotes protein degradation by blocking synthesis of nondegradable forked ubiquitin chains. EMBO J 2009; 28: 1867-1877.
82. Raman M, Havens CG, Walter JC, Harper JW. A genome-wide screen identifies p97 as an essential regulator of DNA damage-dependent CDT1 destruction. Mol Cell 2011; 44: 72-84.
83. Franz A, Orth M, Pirson PA, Sonneville R, Blow JJ, Gartner A et al. CDC-48/p97 coordinates CDT-1 degradation with GINS chromatin dissociation to ensure faithful DNA replication. Mol Cell 2011; 44: 85-96.
84. Meyer H, Bug M, Bremer S. Emerging functions of the VCP/p97 AAA-ATPase in the ubiquitin system. Nat Cell Biol 2012; 14: 117-123.
85. Feng L, Chen J. The E3 ligase RNF8 regulates KU80 removal and NHEJ repair. Nat Struct Mol Biol 2012; 19: 201-206.
86. Tan MK, Lim HJ, Harper JW. SCF(FBXO22) regulates histone H3 lysine 9 and 36 methylation levels by targeting histone demethylase KDM4A for ubiquitinmediated proteasomal degradation. Mol Cell Biol 2011; 31: 3687-3699.
87. Mallette FA, Richard S. K48-linked ubiquitination and protein degradation regulate 53BP1 recruitment at DNA damage sites. Cell Res 2012; 22: 1221-1223.
88. Sauer RT, Bolon DN, Burton BM, Burton RE, Flynn JM, Grant RA et al. Sculpting the proteome with AAA(\+) proteases and disassembly machines. Cell 2004; 119: 9-18.
89. Richly H, Rape M, Braun S, Rumpf S, Hoege C, Jentsch S. A series of ubiquitin binding factors connects CDC48/p97 to substrate multiubiquitylation and proteasomal targeting. Cell 2005; 120: 73-84.
90. Wilcox AJ, Laney JD. A ubiquitin-selective AAA-ATPase mediates transcriptional switching by remodelling a repressor-promoter DNA complex. Nat Cell Biol 2009; 11: 1481-1486.
91. Rumpf S, Jentsch S. Functional division of substrate processing cofactors of the ubiquitin-selective Cdc48 chaperone. Mol Cell 2006; 21: 261-269.
92. Verma R, Oania R, Fang R, Smith GT, Deshaies RJ. Cdc48/p97 mediates UVdependent turnover of RNA Pol II. Mol Cell 2011; 41: 82-92.
93. Ernst R, Claessen JH, Mueller B, Sanyal S, Spooner E, van der Veen AG et al. Enzymatic blockade of the ubiquitin-proteasome pathway. PLoS Biol 2011; 8: e1000605.
94. Livingstone M, Ruan H, Weiner J, Clauser KR, Strack P, Jin S et al. Valosin-containing protein phosphorylation at Ser784 in response to DNA damage. Cancer Res 2005; 65: 7533-7540.
95. Zhang H, Wang Q, Kajino K, Greene MI. VCP, a weak ATPase involved in multiple cellular events, interacts physically with BRCA1 in the nucleus of living cells. DNA Cell Biol 2000; 19: 253-263.
96. Indig FE, Partridge JJ, von Kobbe C, Aladjem MI, Latterich M, Bohr VA. Werner syndrome protein directly binds to the AAA ATPase p97/VCP in an ATPdependent fashion. J Struct Biol 2004; 146: 251-259.
97. Yamada T, Okuhara K, Iwamatsu A, Seo H, Ohta K, Shibata T et al. p97 ATPase, an ATPase involved in membrane fusion, interacts with DNA unwinding factor (DUF) that functions in DNA replication. FEBS Lett 2000; 466: 287-291.
98. Min J, Allali-Hassani A, Nady N, Qi C, Ouyang H, Liu Y et al. L3MBTL1 recognition of mono-and dimethylated histones. Nat Struct Mol Biol 2007; 14: 1229-1230.
99. Lok GT, Sy SM, Dong SS, Ching YP, Tsao SW, Thomson TM et al. Differential regulation of RNF8-mediated Lys48-and Lys63-based poly-ubiquitylation. Nucleic Acids Res 2011; 40: 196-205.
100. Dimitrova N, Chen YC, Spector DL, de Lange T. 53BP1 promotes non-homologous end joining of telomeres by increasing chromatin mobility. Nature 2008; 456: 524-528.
101. Bothmer A, Robbiani DF, Di Virgilio M, Bunting SF, Klein IA, Feldhahn N et al. Regulation of DNA end joining, resection, and immunoglobulin class switch recombination by 53BP1. Mol Cell 2011; 42: 319-329.
102. Hu X, Paul A, Wang B. Rap80 Recruitment to DNA double strand breaks requires binding to both sumo-and ubiquitin-conjugates. J Biol Chem 2012; 287: 25510-25519.
103. Guzzo CM, Berndsen CE, Zhu J, Gupta V, Datta A, Greenberg RA et al. RNF4-dependent hybrid SUMO-ubiquitin chains are signals for RAP80 and thereby mediate the recruitment of BRCA1 to sites of DNA damage. Sci Signal 2012; 5: 88.
104. Wang B, Hurov K, Hofmann K, Elledge SJ. NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. Genes Dev 2009; 23: 729-739.
105. Mok MT, Henderson BR. A comparison of BRCA1 nuclear localization with 14 DNA damage response proteins and domains: identification of specific differences between BRCA1 and 53BP1 at DNA damage-induced foci. Cell Signal 2010; 22: 47-56.
106. Chapman JR, Sossick AJ, Boulton SJ, Jackson SP. BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair. J Cell Sci 2012; 125(Pt 15): 3529-3534.
107. Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010; 17: 688-695.
108. Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010; 141: 243-254.
109. Cao L, Xu X, Bunting SF, Liu J, Wang RH, Cao LL et al. A selective requirement for 53BP1 in the biological response to genomic instability induced by Brca1 deficiency. Mol Cell 2009; 35: 534-541.
110. Gudjonsson T, Altmeyer M, Savic V, Toledo L, Dinant C, Grofte M et al. TRIP12 and UBR5 suppress spreading of chromatin ubiquitylation at damaged chromosomes. Cell 2012; 150: 697-709.
111. Pegoraro G, Voss TC, Martin SE, Tuzmen P, Guha R, Misteli T. Identification of mammalian protein quality control factors by high-throughput cellular imaging. PLoS ONE 2012; 7: e31684.
112. Kristensen CN, Bystol KM, Li B, Serrano L, Brenneman MA. Depletion of DSS1 protein disables homologous recombinational repair in human cells. Mutat Res 2010; 694: 60-64.
113. Zhou Q, Kojic M, Cao Z, Lisby M, Mazloum NA, Holloman WK. Dss1 interaction with Brh2 as a regulatory mechanism for recombinational repair. Mol Cell Biol 2007; 27: 2512-2526.
114. Kojic M, Zhou Q, Lisby M, Holloman WK. Brh2-Dss1 interplay enables properly controlled recombination in Ustilago maydis. Mol Cell Biol 2005; 25: 2547-2557.
115. Liu J, Doty T, Gibson B, Heyer WD. Human BRCA2 protein promotes RAD51 filament formation on RPA-covered single-stranded DNA. Nat Struct Mol Biol 2010; 17: 1260-1262
116. Takeshita T, Wu W, Koike A, Fukuda M, Ohta T. Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents. Cancer Chemotherapy Pharmacol 2009; 64: 1039-1046.
117. Neri P, Ren L, Gratton K, Stebner E, Johnson J, Klimowicz A et al. Bortezomib-induced 'BRCAness' sensitizes multiple myeloma cells to PARP inhibitors. Blood 2011; 118: 6368-6379.
118. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008; 359: 906-917.
119. Chen Q, Van der Sluis PC, Boulware D, Hazlehurst LA, Dalton WS. The FA/BRCA pathway is involved in melphalan-induced DNA interstrand cross-link repair and accounts for melphalan resistance in multiple myeloma cells. Blood 2005; 106: 698-705.
120. Beaven AW, Shea TC, Moore DT, Feldman T, Ivanova A, Ferraro M et al. A phase I study evaluating ibritumomab tiuxetan (Zevalin(R)) in combination with bortezomib (Velcade(R)) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma. Leukemia Lymphoma 2012; 53: 254-258.
121. Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012; 120: 947-959.
122. Dalla Via L, Nardon C, Fregona D. Targeting the ubiquitin-proteasome pathway with inorganic compounds to fight cancer: a challenge for the future. Future Med Chem 2012; 4: 525-543.
123. Ramchandren R. Advances in the treatment of relapsed or refractory Hodgkin's lymphoma. Oncol 2012; 17: 367-376.
124. Cvek B. Proteasome inhibitors. Prog Mol Biol Translational Sci 2012; 109: 161-226.
125. D'Arcy P, Linder S. Proteasome deubiquitinases as novel targets for cancer therapy. Int J Biochem Cell Biol 2012; 44: 1729-1738.
126. Cvek B. Targeting malignancies with disulfiram (Antabuse): multidrug resistance, angiogenesis, and proteasome. Curr Cancer Drug Targets 2011; 11: 332-337.
127. Gallery M, Blank JL, Lin Y, Gutierrez JA, Pulido JC, Rappoli D et al. The JAMM motif of human deubiquitinase Poh1 is essential for cell viability. Mol Cancer Ther 2007; 6: 262-268.
128. Lasker K, Forster F, Bohn S, Walzthoeni T, Villa E, Unverdorben P et al. Molecular architecture of the 26S proteasome holocomplex determined by an integrative approach. Proc Natl Acad Sci USA 2012; 109: 1380-1387.
129. Lander GC, Estrin E, Matyskiela ME, Bashore C, Nogales E, Martin A. Complete subunit architecture of the proteasome regulatory particle. Nature 2012; 482: 186-191.
130. Nijman SM, Luna-Vargas MP, Velds A, Brummelkamp TR, Dirac AM, Sixma TK et al. A genomic and functional inventory of deubiquitinating enzymes. Cell 2005; 123: 773-786.
131. Verma R, Aravind L, Oania R, McDonald WH, Yates 3rd JR, Koonin EV et al. Role of Rpn11 metalloprotease in deubiquitination and degradation by the 26S proteasome. Science 2002; 298: 611-615.
132. Yao T, Cohen RE. A cryptic protease couples deubiquitination and degradation by the proteasome. Nature 2002; 419: 403-407.
133. Nabhan JF, Ribeiro P. The 19 S proteasomal subunit POH1 contributes to the regulation of c-Jun ubiquitination, stability, and subcellular localization. J Biol Chem 2006; 281: 16099-16107.
134. Wertz IE, O'Rourke KM, Zhou H, Eby M, Aravind L, Seshagiri S et al. De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-[kappa]B signalling. Nature 2004; 430: 694-699.
135. Burnett B, Li F, Pittman RN. The polyglutamine neurodegenerative protein ataxin-3 binds polyubiquitylated proteins and has ubiquitin protease activity. Human Mol Genet 2003; 12: 3195-3205.
136. Scheel H, Tomiuk S, Hofmann K. Elucidation of ataxin-3 and ataxin-7 function by integrative bioinformatics. Human Mol Genet 2003; 12: 2845-2852.
137. Liu Y, Fallon L, Lashuel HA, Liu Z, Lansbury Jr PT. The UCH-L1 gene encodes two opposing enzymatic activities that affect a-synuclein degradation and parkinson's disease susceptibility. Cell 2002; 111: 209-218.
138. Lam YA, Xu W, DeMartino GN, Cohen RE. Editing of ubiquitin conjugates by an isopeptidase in the 26S proteasome. Nature 1997; 385: 737-740.
139. Nishio K, Kim SW, Kawai K, Mizushima T, Yamane T, Hamazaki J et al. Crystal structure of the de-ubiquitinating enzyme UCH37 (human UCH-L5) catalytic domain. Biochem Biophys Res Commun 2009; 390: 855-860.
140. Schoenfeld AR, Apgar S, Dolios G, Wang R, Aaronson SA. BRCA2 is ubiquitinated in vivo and interacts with USP11, a deubiquitinating enzyme that exhibits prosurvival function in the cellular response to DNA damage. Mol Cell Biol 2004; 24: 7444-7455.
141. Brummelkamp TR, Nijman SMB, Dirac AMG, Bernards R. Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-[kappa]B. Nature 2003; 424: 797-801.
142. Kovalenko A, Chable-Bessia C, Cantarella G, Israel A, Wallach D, Courtois G. The tumour suppressor CYLD negatively regulates NF-[kappa]B signalling by deubiquitination. Nature 2003; 424: 801-805.
143. Trompouki E, Hatzivassiliou E, Tsichritzis T, Farmer H, Ashworth A, Mosialos G. CYLD is a deubiquitinating enzyme that negatively regulates NF-[kappa]B activation by TNFR family members. Nature 2003; 424: 793-796.
144. Nijman SMB, Huang TT, Dirac AMG, Brummelkamp TR, Kerkhoven RM, D'Andrea AD et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell 2005; 17: 331-339.
145. Russell NS, Wilkinson KD. Identification of a novel 29-linked polyubiquitin binding protein, Ufd3, using polyubiquitin chain analoguesw,z. Biochemistry 2004; 43: 4844-4854.